Semax Neuroprotection Research: Published Studies Reviewed
A factual review of peer-reviewed studies investigating Semax, a synthetic heptapeptide analog of ACTH(4-7), in neuroprotection, BDNF regulation, and cognitive function models.
Semax: Overview
Semax (MEHFPGP) is a synthetic heptapeptide derived from the 4โ7 fragment of adrenocorticotropic hormone (ACTH). Unlike full-length ACTH, Semax lacks adrenocortical activity โ it does not stimulate cortisol release. Instead, the 4โ7 fragment retains the neuropeptide signaling properties of the parent molecule while being structurally stabilized by a synthetic Pro-Gly-Pro C-terminal extension that resists enzymatic degradation. Semax has been investigated primarily in Russian and Eastern European preclinical and clinical research since the 1980s, with a focus on BDNF modulation, neuroprotection, and learning/memory models. The following review presents key findings from published research without therapeutic claims or dosage recommendations.
Study 1: BDNF and Neurotrophin Expression
Multiple preclinical studies have examined Semax's effects on brain-derived neurotrophic factor (BDNF) expression โ a neurotrophin critical for neuronal survival, synaptic plasticity, and hippocampal long-term potentiation.
Research into BDNF and NGF expression revealed:
- BDNF mRNA upregulation in hippocampus and basal forebrain
- NGF (nerve growth factor) mRNA also increased in hippocampal tissue
- trkB receptor expression (BDNF's primary signaling receptor) upregulated in some regions
- Effects dose-dependent in rat models
- Transcriptional changes preceded downstream protein level increases by 24โ48 hours
Study 2: Neuroprotection in Experimental Ischemia
Significant research on Semax has been conducted in stroke and cerebral ischemia models, where protection of neuronal tissue from ischemic damage has been the primary endpoint.
Neuroprotective effects in ischemia models included:
- Reduced infarct volume in multiple MCAO rodent models
- Decreased expression of pro-inflammatory cytokines (IL-1ฮฒ, TNF-ฮฑ) in ischemic brain regions
- Preservation of mitochondrial membrane potential in neurons exposed to ischemic conditions
- Enhanced survival of neurons in peri-infarct (penumbra) zones
- Anti-apoptotic effects observed in in vitro neuronal oxygen-glucose deprivation models
Additional context: Semax is registered as a drug in Russia (Pharmsyntez) and has been used in clinical practice there for stroke recovery. This clinical experience, while not equivalent to Western regulatory approval, adds context to the preclinical findings.
Proposed Mechanisms Under Investigation
Unlike some neuropeptides with well-defined single-receptor mechanisms, Semax's pharmacological profile appears to involve multiple systems. The following pathways have been implicated in preclinical research:
| Mechanism | Research Evidence Level |
|---|---|
| BDNF/NGF upregulation | Rodent hippocampal mRNA and protein studies; moderate preclinical evidence |
| Melanocortin receptor activity | ACTH(4-7) fragment may interact with MC4R; pharmacological data mixed |
| Serotonin system modulation | Some studies report 5-HT system changes; mechanism unclear |
| NMDA receptor interaction | In vitro data suggests possible modulation; not yet well-characterized |
| Dopaminergic activity | Preclinical rodent studies show dopamine turnover changes in striatum |
The relative importance of each mechanism in observed behavioral and neuroprotective effects remains under investigation.
Cognitive Function Studies
Several research groups have examined Semax in learning and memory paradigms in rodents, including Morris water maze, radial arm maze, and passive avoidance tests.
Findings in cognitive models:
- Improved spatial memory acquisition in Morris water maze in multiple rodent studies
- Enhanced passive avoidance retention in acute stress models
- Improved maze performance in aged rats โ suggesting relevance to age-associated cognitive decline models
- Hippocampal LTP enhancement in electrophysiological recordings from Semax-treated animals
Molecular Profile
| Property | Value |
|---|---|
| Full name | Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) |
| Parent sequence | ACTH(4-7) with C-terminal Pro-Gly-Pro stabilization |
| Molecular weight | ~874 Da |
| Primary research contexts | Neuroprotection, BDNF modulation, cognitive function |
| Origin | Developed at Institute of Molecular Genetics, Russian Academy of Sciences |
| Storage | Lyophilized: -20ยฐC; Reconstituted: 2โ8ยฐC, use within 30 days |
Quick Reference Summary
- Origin: Synthetic heptapeptide derived from ACTH(4-7); no adrenocortical activity
- Key mechanism research: BDNF and NGF upregulation in hippocampal tissue
- Neuroprotection: Reduced infarct volume and preserved peri-infarct neurons in ischemia models
- Cognitive research: Improved spatial memory and LTP enhancement in rodent models
- Research context: Extensively studied in Russian literature; limited Western peer review
- Use context: Research-grade compound for in vitro and preclinical laboratory use only